Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989202 | 0.78 | CFTR (0.42) | ACVR1TSHRP2RX7 | |
| SCHEMBL2372492 | 0.74 | CFTR (0.41) | ACVR1P2RX7 | |
| SCHEMBL2373135 | 0.72 | CD274 (0.51) | ALDH1A1HPGDTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL2382610 | 0.72 | THRB (0.51) | ALDH1A1LMNATSHRKMT2A | |
| SCHEMBL2372053 | 0.72 | P2RX7 (0.51) | LMNATSHRP2RX7 | |
| SCHEMBL2383186 | 0.71 | POLB (0.56) | ALDH1A1LMNATSHRP2RX7KMT2A | |
| SCHEMBL2372591 | 0.71 | ALDH1A1 (0.44) | CYP3A4CYP2C19ALDH1A1ACVR1L3MBTL1 | |
| SCHEMBL14784270 | 0.68 | CFTR (0.42) | ALDH1A1P2RX7NPC1GAA | |
| SCHEMBL2372260 | 0.64 | CFTR (0.38) | ALDH1A1HPGDHTT | |
| SCHEMBL14816567 | 0.64 | PLAU (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CYP3A4 312/4885CYP2C19 456/4885ALDH1A1 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.